

## DAFTAR PUSTAKA

- American Heart Association, 1998. Heart and Stroke Statistical Update; *American Heart Association*: Dallas, TX, USA..
- Arnold, R.J.G., 2010 (eds.). *Pharmacoeconomics from Theory to Practice*, CRC Press, New York.
- Backhouse, M.E., Richter, A., Gaffney, L., 2005. Economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events. *J Med Econ*;3:97-109.
- Badan Penelitian dan Pengembangan Kesehatan, 2007. Laporan Hasil Riset Kesehatan Dasar (RISKESDAS) Nasional. Departemen Kesehatan RI, Jakarta.
- Badan Penelitian dan Pengembangan Kesehatan, 2013. Laporan Hasil Riset Kesehatan Dasar (RISKESDAS) Nasional. Departemen Kesehatan RI, Jakarta.
- Cleland, J.G., Tendera, M., Adamus, J., 2006. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. *Eur Heart J*. 27(19):2338-2345.
- Davies, M.K., Gibbs, C.R., Lip, G.Y.H., 2000. ABC of heart failure: management: diuretics, ACE inhibitors, and nitrates. *BMJ*;320:428-31.
- DINKES Provinsi Jawa Tengah, 2009. Profil Kesehatan Provinsi Jawa Tengah. DINKES Provinsi Jawa Tengah, Semarang.
- Flather, M.D., Yusuf, S., Kober, L., Pfeffer, M., Hall, A., Murray, G., 2000. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. *Lancet*::355(9215):1575-81.
- Faris, R., Flather, M., Purcell, H., Henein, M., Coats, W.P., 2002. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. *Int J Cardiol* 82(2):149-58.
- Francis, G.S., 2004. Acute heart failure: patient management of a growing epidemic, *Am Heart Hosp J*. 2(1): 10-4.
- Göhler, A., Geisler, B.P., Manne, J.M., Kosiborod, M., Zhang, Z., Weintraub, W.S., Spertus, J.A., Gazelle, S., Siebert, U., Cohen D.J., 2008. Utility Estimates for Decision-Analytic Modeling in Chronic Heart Failure—Health States Based on New York Heart Association Classes and Number of Rehospitalizations. *ISPOR* 12: 185-7.
- Guiqing, Y., Nick, F., Marcus, F., Puvan, T., Andrew, C., Philip, A.P.W., 2008. Long-Term Cost-Effectiveness Analysis of Nebivolol Compared with

- Standard Care in Elderly Patients with Heart Failure. *Pharmacoeconomics*: 26 (10):879-889.
- Lloyd-Jones, D., Adams, R.J., Brown, T.M., Carnethon, M., ai, S., & imone, G.D. 2010. Heart disease and stroke statistics—2010 update. a report from the american heart association. *Circulation*. 121: e129-e133.
- Loehr, L.R., Rosamond, W.D., Chang, P.P., Folsom, A.R., Chambless, L.E., 2008. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). *Am J Cardiol*. 101:1016–1022.
- Malik, I.S., Bhatia, V.K., Kooner, J.S., 2001. Cost effectiveness of ramipril treatment for cardiovascular risk reduction. *Heart*;85:539-43.
- Maggioni, A.P., 2005. Review of the new ESC guidelines for the pharmacological management of chronic heart failure. *European Heart Journal*. 7 (Suppl J) :J15-J20.
- McGhan, W.F., 2010. Introduction to Pharmacoeconomics in Arnold, R.J.G., et al, editors, *Pharmacoeconomics from Theory to Practice*, CRC Press, New York.
- McKee, P.A.; Castelli, W.P.; McNamara, P.M.; Kannel, W.B. 1971. The natural history of congestive heart failure: the Framingham study. *N. Engl. J. Med.*, 285, 1441-1446.
- McMurray, J., Davie, A., 1996. The pharmacoeconomics of ACE inhibitors in chronic heart failure. *Pharmacoeconomics* 9(3):188-97.
- NCHS, 2006. National Hospital Discharge Survey: 2006 Annual Summary. Maryland.
- National Institute for Health and Clinical Excellence, 2010. *Chronic Heart Failure: Management of Chronic Heart Failure in Adults in Primary and Secondary Care (NICE Clinical Guideline 108)*. London.
- NHLBI, 2007. Incidence and Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases. Bethesda.
- O’Connell, J.B., Bristow, M.R., 1994. Economic impact of heart failure in the United States: Time for a different approach. *J Hean Lung Transplant*; 13:s 107-S 112.
- Packer, M., Wilson, P.A.P., Armstrong, P.W., Cleland, J.G.F., Horowitz, J.D., Massie, B.M., et al., 1999. Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure. *Circulation* 100:2312-2318.
- Peacock, W.F., 2003. “Clinical and Economic Impact of Nesiritide.” *American Journal of Health System Pharmacy* 60 (suppl 4): S21–5.

- Pfeffer, M.A., Braunwald, E., Moye, L.A., 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med*;327(10):669–677.
- Pitt, B., Zannad, F., Remme, W.J., 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure (RALES). *N Engl J Med*; 341 (10):709-717.
- Riley, G.F., 2007. Long-term trends in the concentration of Medicare spending. *Health Aff (Millwood)* 26:808–816.
- Roger, V.L., 2010. The Heart Failure Epidemic. *Int. J. Environ. Res. Public Health* 7: 1807-1830.
- SA Grover, L Coupal, I Lowensteyn. Determining the costeffectiveness of preventing cardiovascular disease: Are estimatescalculated over the duration of a clinical trial adequate? *Can J Cardiol* 2008;24(4):261-266.
- Sanchez, L.A., 2005, *Pharmacoeconomics: Principles, methods, and Application*. in Dipiro, J.T., Talbert, L.R., *et al*, editors. *Pharmacotherapy a patophysiology approach, 6<sup>th</sup> ed*, McGraw Hill, New York.
- Santoso, A., Erwinanto, Munawar, M., Suryawan, R., Rifqi, S., Soerianata, S., 2007. *Diagnosis dan tatalaksana praktis gagal jantung akut*. Semarang.
- Spannheimer, A., Goertz, A., Dreckmann, B.B., 1998. Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. *Int J Clin Pract*;52:467–71
- Steven, A.G., Louis, C., Ilka, L., 2008. Determining the cost-effectiveness of preventing cardiovascular disease: Are estimates calculated over the duration of a clinical trial adequate? *Can J Cardiol*;24(4):261-266.
- Tilson L., McGowan B., Ryan M., Barry M., 2003. Cost-effectiveness of spironolactone in patients with severe heart failure. *IJMS*;172(2):70-72.
- Watson, R.D.S, Gibbs, C.R, Lip, G.Y.H., 2000. ABC of heart failure: clinical features and complications. *BMJ*; 320: 236-9.